Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Mono PharmacareNSE:MONOPHARMA -4.21%9 Buyback Yield % is 0.00 as of Aug. 05, 2026. GuruFocus rates NSE:MONOPHARMA with a GF Score™ of 9/100. The stock has 6 warning signs investors should review. Among 271 Healthcare Providers & Services companies, Mono Pharmacare ranks worse than 369003.32% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
The historical data trend for Mono Pharmacare's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Pharmaceutical Retailers subindustry, Mono Pharmacare's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mono Pharmacare Buyback Yield % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Mono Pharmacare's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Mono Pharmacare's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mono Pharmacare (NSE:MONOPHARMA) has a Buyback Yield % of 0.00 as of Aug. 05, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Mono Pharmacare and its competitors. According to the industry distribution chart, Mono Pharmacare ranks #999999 out of 271 companies in the Healthcare Providers & Services industry.
Is Mono Pharmacare's Buyback Yield % too high?
Mono Pharmacare's current Buyback Yield % is 0.00. Based on the distribution chart, Mono Pharmacare ranks #999999 out of 271 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Mono Pharmacare has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Mono Pharmacare's Buyback Yield % compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Mono Pharmacare ranks #999999 out of 271 companies for Buyback Yield %. This places Mono Pharmacare in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Healthcare Providers & Services company?
A good Buyback Yield % depends on the Healthcare Providers & Services industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Mono Pharmacare and its competitors. Mono Pharmacare's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mono Pharmacare stock overvalued right now?
Mono Pharmacare (NSE:MONOPHARMA) has a current Buyback Yield % of 0.00. The current Buyback Yield % is 0.00. Mono Pharmacare's overall GF Score™ is 9/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Mono Pharmacare (NSE:MONOPHARMA), the current Buyback Yield % is 0.00 as of Aug. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Mono Pharmacare Ltd distributes a broad range of pharmaceutical products across India. Its portfolio includes antibiotics, antifungal medicines, cough and cold remedies, antacids, analgesics, nutraceuticals, skincare, antiseptics, cardiac and diabetic drugs, and cosmetic items. The company operates through contract manufacturing, sourcing products from various manufacturers and supplying them to healthcare providers and pharmacies. Revenue is generated through the sales and distribution of these pharmaceutical and healthcare products in the Indian market.
9GF Score
Get the complete analysis for NSE:MONOPHARMA
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:MONOPHARMA has been successfully added to your 
